EyePoint’s Phase 3 trial of duravyu fails to outperform aflibercept, shares plunge 70%

EyePoint announced that its Phase 3 Lugano trial of the investigational tyrosine kinase inhibitor duravyu did not meet the primary efficacy endpoint when compared with the standard‑of‑care anti‑VEGF drug aflibercept for wet age‑related macular degeneration.

The study enrolled roughly 400 patients and evaluated the average change in best corrected visual acuity over two years. Aflibercept produced a mean improvement of more than five letters, whereas duravyu showed a change ranging from zero to five letters.

The company released limited details beyond the missed endpoint, and its shares dropped about 70% to $4.28 per share in early trading.

The setback adds pressure on future readouts for the same asset and highlights the intense competition in next‑generation AMD therapies.